Business
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
BRISBANE, Calif., February 03, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, hel
About this update from Caredx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/2059cb5ae12d80485206fb16b5af8154"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KAIWtFSN6JzYrsYTMlNHcw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2059cb5ae12d80485206fb16b5af8154","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/C8xW1QrHX0zzLOvL8oU4Pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/2059cb5ae12d80485206fb16b5af8154","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Company to host investor webcast and conference call on February 12 at 7 a.m. PT / 10 a.m. ET","length":93,"tagName":"p"},{"type":"text","content":"Investor webcast will feature the clinical validation data and review commercial launch timeline","length":96,"tagName":"p"},{"type":"text","content":"BRISBANE, Calif., February 03, 2026--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, held February 4-7, 2026, in Salt Lake City, Utah.","length":567,"tagName":"p"},{"type":"text","content":"The ACROBAT study is a prospective, multi-center, blinded clinical trial evaluating AlloHeme, CareDx’s AI-powered next-generation sequencing (NGS)-based peripheral blood test for monitoring relapse after allogeneic hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. AlloHeme identifies cancer relapse ahead of traditional detection methods, potentially enabling timely clinical interventions. The ACROBAT study includes patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) monitored with AlloHeme for cancer relapse at 11 hematopoietic stem cell transplant centers across the U.S.","length":639,"tagName":"p"},{"type":"text","content":"The oral ...